By Regulatory Approvals — FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC Urology Times
Read the original at Regulatory Approvals ↗
Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. November 13, 2026.